Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung

Pediatric Blood and Cancer

Volumn 60, Issue 4, 2013, Pages 580-586

  Chou, Alexander J ^a   Gupta, Renu ^b   Bell, Moshe D ^c   Riewe, Kathleen O'Day ^c   Meyers, Paul A ^a   Gorlick, Richard ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Insmed Inc   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Clinical trials, inhaled cisplatin; New agents; Recurrent osteosarcoma

Indexed keywords

CISPLATIN DERIVATIVE; LIPID CISPLATIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURGERY; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; DRY NOSE; DYSGEUSIA; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATION; LUNG FUNCTION; LUNG METASTASIS; MALE; MEDICAL NEBULIZER; METASTASIS RESECTION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OPEN STUDY; OSTEOSARCOMA; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REHYDRATION; RESPIRATORY DISTRESS; RHINORRHEA; SIDE EFFECT; SINUS CONGESTION; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VOMITING; WHEEZING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CISPLATIN; FEMALE; HUMANS; LIPIDS; LUNG NEOPLASMS; MALE; OSTEOSARCOMA; YOUNG ADULT;

EID: 84873702613     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24438     Document Type: Article

References (44)

1. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98: 2447-2456.
2. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: The memorial Sloan-Kettering cancer center experience. Cancer 2005; 104: 2214-2221.
3. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
4. Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 2003; 39: 2050-2057.
5. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
6. Kayton ML. Pulmonary metastasectomy in pediatric patients. Thorac Surg Clin 2006; 16: vi167-vi183.
7. Kayton ML, Huvos AG, Casher J, et al. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Pediatr Surg 2006; 41: 200-206; discussion 200-206.
8. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009; 27: 557-565.
9. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: Innate biology versus treatment-specific. J Pediatr Hematol Oncol 2003; 25: 840-841.
10. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-2458.
11. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
12. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21: 3072-3078.
13. Wittgen BP, Kunst PW, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007; 13: 2414-2421.
14. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
15. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
16. Bielack SS, Erttmann R, Looft G, et al. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS. Cancer Chemother Pharmacol 1989; 24: 376-380.
17. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 1983; 51: 402-407.
18. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-417.
19. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003; 5: 114-125.
20. Rollins KD, Lindley C. Pemetrexed: A multitargeted antifolate. Clin Ther 2005; 27: 1343-1382.
21. Solomon B, Bunn PA, Jr. Clinical activity of pemetrexed: A multitargeted antifolate anticancer agent. Future Oncol 2005; 1: 733-746.
22. Fleisher M. Antifolate analogs: Mechanism of action, analytical methodology, and clinical efficacy. Ther Drug Monit 1993; 15: 521-526.
23. Trippett T, Meyers P, Gorlick R, et al. High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: A Phase II trial. Proceedings of the American Society of Clinical Oncology annual meeting. 1999.
24. Takemura Y, Kobayashi H, Miyachi H. Antifolate resistance and its circumvention by new analogues. Hum Cell 2001; 14: 185-202.
25. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
26. Herzlieb N, Gallaher BW, Berthold A, et al. Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor. Cell Mol Biol (Noisy-le-grand) 2000; 46: 71-77.
27. Yang JL, Crowe PJ. Targeted therapies in adult soft tissue sarcomas. J Surg Oncol 2007; 95: 183-184.
28. von Mehren M. New therapeutics for soft-tissue sarcomas in adults. Oncology (Williston Park) 2007; 21: 123-126.
29. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-1802.
30. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 2006; 18: 354-359.
31. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-1197.
32. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008; 19: 807-813.
33. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003; 21: 167-176.
34. Alberts DS, Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31: 53-90.
35. Chou AJ, Bell MD, Mackinson C, et al. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I 2007:25(18S; Abstract #9525).
36. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5: 2316-2323.
37. Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 2006; 8: 310-315.
38. Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003; 3: 239-250.
39. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
40. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25: 6436-6446.
41. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-2411.
42. Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol 1985; 8: 77-80.
43. Lewis MJ, DuBois SG, Fligor B, et al. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52: 387-391.
44. Shevchenko IT, Resnik GE. Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma 1968; 15: 419-426.